A novel in vitro filter trap assay identifies tannic acid as an amyloid aggregation inducer for HET-s

被引:11
作者
Boye-Harnasch, Mona [1 ]
Cullin, Christophe [1 ]
机构
[1] CNRS, UMR 5095, Inst Biochim & Genet Cellulaire, F-33077 Bordeaux, France
关键词
prion; amyloid; filter trap assay; HET-s; tannic acid;
D O I
10.1016/j.jbiotec.2006.03.006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 0836 [生物工程]; 090102 [作物遗传育种]; 100705 [微生物与生化药学];
摘要
In this work we present an easy and low cost in vitro filter trap assay to quickly identify direct actors on amyloid prion aggregation. We chose the recombinant purified prion protein HET-s from Podospora anserina as a reference. HET-s was labelled with a fluorophore prior to aggregation assays in a 96 well micro-array system. Aggregation assays were carried out in presence of a number of chemical compounds, followed by a filter trap assay through a cellulose acetate membrane and the straight detection of retained fluorescent amyloid fibres. We tested 22 chemical compounds from which 11 have already been described to affect various prions and other amyloid proteins. Four compounds showed direct effects on the aggregation of HET-s. ZnCl seemed to prevent the formation of amyloid fibres. Puzzlingly, three members of the group of tannins (tannic acid, epigallocatechin and epigallocatechin-gallate) had accelerant properties on amyloid aggregation. Resistance of the prion forming domain (PFD) in Proteinase K proteolysis assays underlined that tannic acid favours amyloid fibre formation of HET-s. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:222 / 230
页数:9
相关论文
共 28 条
[1]
Isolation of drugs active against mammalian prions using a yeast-based screening assay [J].
Bach, S ;
Talarek, N ;
Andrieu, T ;
Vierfond, JM ;
Mettey, Y ;
Galons, H ;
Dormont, D ;
Meijer, L ;
Cullin, C ;
Blondel, M .
NATURE BIOTECHNOLOGY, 2003, 21 (09) :1075-1081
[2]
The sequences appended to the amyloid core region of the HET-s prion protein determine higher-order aggregate organization in vivo [J].
Balguerie, A ;
Dos Reis, S ;
Coulary-Salin, B ;
Chaignepain, S ;
Sabourin, M ;
Schmitter, JM ;
Saupe, SJ .
JOURNAL OF CELL SCIENCE, 2004, 117 (12) :2599-2610
[3]
In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features [J].
Baskakov, IV ;
Bocharova, OV .
BIOCHEMISTRY, 2005, 44 (07) :2339-2348
[4]
In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrPSc [J].
Bocharova, OV ;
Breydo, L ;
Parfenov, AS ;
Salnikov, VV ;
Baskakov, IV .
JOURNAL OF MOLECULAR BIOLOGY, 2005, 346 (02) :645-659
[5]
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases [J].
Bucciantini, M ;
Giannoni, E ;
Chiti, F ;
Baroni, F ;
Formigli, L ;
Zurdo, JS ;
Taddei, N ;
Ramponi, G ;
Dobson, CM ;
Stefani, M .
NATURE, 2002, 416 (6880) :507-511
[6]
Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems - An update [J].
Caughey, B ;
Raymond, GJ ;
Priola, SA ;
Kocisko, DA ;
Race, RE ;
Bessen, RA ;
Lansbury, PT ;
Chesebro, B .
MOLECULAR BIOTECHNOLOGY, 1999, 13 (01) :45-55
[7]
Inhibition of protease-resistant prion protein accumulation in vitro by curcumin [J].
Caughey, B ;
Raymond, LD ;
Raymond, GJ ;
Maxson, L ;
Silveira, J ;
Baron, GS .
JOURNAL OF VIROLOGY, 2003, 77 (09) :5499-5502
[8]
From conversion to aggregation: Protofibril formation of the prion protein [J].
DeMarco, ML ;
Daggett, V .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (08) :2293-2298
[9]
The HET-s prion protein of the filamentous fungus Podospora anserina aggregates in vitro into amyloid-like fibrils [J].
Dos Reis, S ;
Coulary-Salin, B ;
Forge, V ;
Lascu, I ;
Bégueret, J ;
Saupe, SJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (08) :5703-5706
[10]
The prion curing agent guanidinium chloride specifically inhibits ATP hydrolysis by Hsp104 [J].
Grimminger, V ;
Richter, K ;
Imhof, A ;
Buchner, J ;
Walter, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (09) :7378-7383